Soliton (NASDAQ:SOLY) has filed a 510(k) submission for FDA clearance of its Rapid Acoustic Pulse (RAP) technology for reduction in the appearance of cellulite, which affects between 80% and 90% of women. The FDA has...
NeuroOne (OTCQB:NMTC) is developing high-definition, minimally invasive thin-film electrodes for the diagnosis and treatment of various neurological conditions, including epilepsy, Parkinson’s disease (PD) and chronic...
Unlike the traditional approach to immunotherapy, which teaches the body to recognize tumor antigens as something foreign to be attacked, closely-held Loki Therapeutics’ AWAKE technology makes cancer appear as something...
Passage Bio (NASDAQ:PASG) is focused on developing transformative, differentiated therapies for rare, life-threatening monogenic CNS disorders, with the goal of mitigating development risk. “We believe that our rigorous...
CohBar (NASDAQ:CWBR) is transforming peptides encoded and expressed by mitochondria, some of which control a wide range of systems in the body, into novel therapeutics. “Harnessing the power of mitochondria biology to...
Cidara Therapeutics (NASDAQ:CDTX) is developing what may be the first antifungal to be approved in 15 years for both the treatment and prevention of invasive fungal disease.
In his role as SVP of life sciences, Ian Koenig brings broad experience to Investis Digital in communications strategy, digital marketing, investor relations and business development on behalf of biopharma globally. Mr...
As a VP of Independent Trading Group (ITG), an issuer designated market making firm, Chris Kaplan brings a more institutional approach to provide liquidity for clients with stocks that are thinly traded. ITG, which is...
Closely-held SetPoint Medical is pioneering electric stimulation of the vagus nerve in the neck as a treatment for rheumatoid arthritis (RA) and other chronic autoimmune diseases, such as Crohn’s disease, ulcerative...
After abruptly ending its hepatitis B virus program in January, Spring Bank Pharmaceuticals (NASDAQ:SBPH) is in the early stages of examining whether its family of RIG-I agonists have the potential to attack SARS-CoV-2...